The Capital Efficiency of Repurposed Innovation Pharmaceutical companies face a brutal economic reality. Developing a new chemical entity now requires […]
How To Turn Known Molecules Into Proprietary Assets Read Post »
The pharmaceutical industry operates on a punishing mathematical reality. In 2024, generic and biosimilar medicines accounted for 90% of all
Trust is the new patent: How to charge 40% more for the same pill Read Post »
Money is moving. The global pharmaceutical industry is currently witnessing a structural relocation of profit that will redefine the balance
The Trust Proxy: How To Capture The 40% Emerging Market Revenue Shift Read Post »
The Pricing Shock: How the Inflation Reduction Act Rewrites the Valuation Rules The economic foundations of the pharmaceutical industry are
The Data-Driven Guide to Winning the 2026 Patent Cliff Read Post »
Direct-to-consumer (DTC) pharmaceutical companies are no longer just apps for convenience. Hims & Hers and Ro have spent the last
Owning the Molecule and the Mailbox: Why Vertical Integration is Pharma’s New Patent Read Post »
The economics of the leaky bucket In the pharmaceutical business, time is the only currency that truly matters. Inventors often
How to keep your drug on the market for five extra years Read Post »
The Ticking Clock: Why Patent Expiration is the Most Important Date in Pharma In pharmaceutical finance and strategy, a single
Patent Expiration Dates: The Calendar Every Pharmaceutical Investor Watches Read Post »
The era of easy arbitrage is over. If you have spent the last three years running a 503B outsourcing facility,
How to Survive the GLP-1 Patent War: A Strategic Manual for 503B Outsourcing Facilities Read Post »
The Crucible of Market Dominance: A Paradigm Shift In pharmaceutical and biotechnology innovation patent litigation is not a mere legal
The Cost of Combat: Deconstructing Drug Patent Litigation in the Pharmaceutical Age Read Post »
Sign in or create a free account to read this DrugPatentWatch article
